Provided by Tiger Trade Technology Pte. Ltd.

GW Pharmaceuticals PLC

218.96
0.0000
Volume:- -
Turnover:- -
Market Cap:6.91B
PE:-98.44
High:218.96
Open:218.96
Low:218.96
Close:218.96
52wk High:219.57
52wk Low:87.07
Shares:31.54M
Float Shares:30.54M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2244
EPS(LYR):-1.8572
ROE:-7.92%
ROA:-3.55%
PB:9.32
PE(LYR):-117.90

Loading ...

Company Profile

Company Name:
GW Pharmaceuticals PLC
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.